Quantcast

Latest Hemarthrosis Stories

2012-01-09 14:31:15

A Rush University Medical Center led international research team has announced that a treatment to prevent bleeding episodes in children with hemophilia A also is effective for adolescents and adults. The preventive therapy will “optimize care for hemophilia patients of all ages by stopping unexpected bleeding events that can have a detrimental impact on the lives of patients,” said Dr. Leonard Valentino, director of the Rush Hemophilia and Thrombophilia Center and principal...

2011-11-08 06:47:57

(Ivanhoe Newswire) — A new drug commonly used to treat bleeding events in people with severe hemophilia can also be used to prevent such events from happening at all, according to this study. An international research team led by Dr. Cindy Leissinger of Tulane University School of Medicine, along with Dr. Alessandro Gringeri from the University of Milan, examined the ability of FEIBA to prevent bleeds in people with severe hemophilia A with inhibitors. People with this condition...

2011-11-04 10:24:50

An international research team led by Dr. Cindy Leissinger of Tulane University School of Medicine, along with Dr. Alessandro Gringeri from the University of Milan, has found that a drug commonly used to treat bleeding events in people with a type of severe hemophilia can also be used to prevent such events from happening in the first place. The study, the first to confirm the efficacy and safety of the drug FEIBA in bleed prevention is published in the Nov. 3, 2011 issue of the New England...

2010-08-02 09:00:00

CHICAGO and HOBOKEN, N.J., Aug. 2 /PRNewswire/ -- Octapharma USA today announced the first grant recipient of the Octapharma 25th Anniversary Grants Program is the Rush Hemophilia & Thrombophilia Center at Rush University Medical Center. The Octapharma grants program supports clinical or pre-clinical research focused on human protein therapies in hematology, immune therapy, intensive care and emergency medicine. Leonard A. Valentino, M.D., Director of the Section of Pediatric...

2008-10-13 09:00:48

Bayer HealthCare has announced that the FDA has approved routine prophylaxis with Kogenate FS Antihemophilic Factor to reduce the frequency of bleeding episodes and the risk of joint damage in patients aged 0-16 years with severe hemophilia A with no pre-existing joint damage. This important approval provides these patients with the only factor VIII treatment that the FDA has determined safe and effective for routine prophylaxis - a treatment regimen recommended by the National Hemophilia...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'